When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
TKPHF - Takeda's Alunbrig approved as a first-line treatment for ALK+ NSCLC in Europe
Takeda Pharmaceutical Co Ltd
The European Commission has extended Takeda Pharmaceutical's (OTCPK:TKPHF) current marketing authorization of ALUNBRIG (brigatinib) to include use as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
More news on: Takeda Pharmaceutical Company Limited, Healthcare stocks news,